NCT03668249

Brief Summary

The descriptive purpose of this study is to characterize clinical and nonclinical factors of participants with CD, participant flow and visits to other specialists in the hospitals of the healthcare network of the Autonomous Community of Madrid with implementation of electronic medical records. The clinical and nonclinical factors include: demographic and baseline clinical characteristics, lifestyle, relapses, complications, day hospital visits, surgery, presence of complications such as perianal fistulas and complex perianal fistulas. The predictive purpose of this study is to develop a statistical predictive model with the information obtained from the descriptive purpose, in the hospitals of the healthcare network of the Autonomous Community of Madrid, capable of assigning any participant diagnosed with CD a probability of reaching a prototypical clinical condition or a probability of experiencing certain clinical complications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,938

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2018

Shorter than P25 for all trials

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 11, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 12, 2018

Completed
14 days until next milestone

Study Start

First participant enrolled

September 26, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 16, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 16, 2019

Completed
Last Updated

October 3, 2019

Status Verified

October 1, 2019

Enrollment Period

12 months

First QC Date

September 11, 2018

Last Update Submit

October 2, 2019

Conditions

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (7)

  • Number of Participants who had Relapses

    Approximately 5 years

  • Number of Participants who had Disease Related Complications

    Approximately 5 years

  • Number of day Hospital Visits

    Approximately 5 years

  • Number of Participants who had Surgeries

    Approximately 5 years

  • Number of Participants with Complications Such as Perianal Fistulas and Complex Perianal Fistulas

    approximately 5 years

  • Participant Flow

    Approximately 5 years

  • Number of Participants who Visit to Other Specialists

    Approximately 5 years

Secondary Outcomes (4)

  • Prevalence of the Different Phenotypes

    Approximately 5 years

  • Number of Participants who met the Eligibility Criteria to Receive Biological Treatment for CD

    Approximately 5 years

  • Number of Direct and Indirect Resources Used

    Approximately 5 years

  • Number of Essential Factors on Which Physician's Predictions of Participant Outcomes are Based

    Approximately 5 years

Study Arms (1)

All Participants

Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.

Eligibility Criteria

AgeUp to 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants diagnosed with CD, will be observed retrospectively.

You may qualify if:

  • \. Diagnosed with CD from the medical centers participating in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

HM Hospitales

Boadilla, Madrid, 28660, Spain

Location

H. U. de Fuenlabrada

Fuenlabrada, Madrid, 28942, Spain

Location

H.U. Puerta de Hierro - Majadahonda

Majadahonda, Madrid, 28222, Spain

Location

H.U. Rey Juan Carlos

Móstoles, Madrid, 28933, Spain

Location

H.U. Infanta Sofia

San Sebastián de los Reyes, Madrid, 28703, Spain

Location

H. U. Infanta Elena

Valdemoro, Madrid, 28342, Spain

Location

H Infanta Leonor y Virgen de la Torre

Vallecas, Madrid, 28031, Spain

Location

H La Princesa

Madrid, 28006, Spain

Location

Related Publications (1)

  • Gomollon F, Gisbert JP, Guerra I, Plaza R, Pajares Villarroya R, Moreno Almazan L, Lopez Martin MC, Dominguez Antonaya M, Vera Mendoza MI, Aparicio J, Martinez V, Tagarro I, Fernandez-Nistal A, Lumbreras S, Mate C, Montoto C; Premonition-CD Study Group. Clinical characteristics and prognostic factors for Crohn's disease relapses using natural language processing and machine learning: a pilot study. Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):389-397. doi: 10.1097/MEG.0000000000002317.

MeSH Terms

Conditions

Inflammatory Bowel DiseasesCrohn Disease

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Study Officials

  • Medical Director

    Takeda

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2018

First Posted

September 12, 2018

Study Start

September 26, 2018

Primary Completion

September 16, 2019

Study Completion

September 16, 2019

Last Updated

October 3, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will share

Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Locations